Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Non Operating Income: 2014-2025

Historic Non Operating Income for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $4.1 million.

  • Theravance Biopharma's Non Operating Income rose 192.51% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 27.73%. This contributed to the annual value of $4.9 million for FY2024, which is 46.46% down from last year.
  • Per Theravance Biopharma's latest filing, its Non Operating Income stood at $4.1 million for Q3 2025, which was up 184.08% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Non Operating Income ranged from a high of $4.1 million in Q3 2025 and a low of -$375,000 during Q1 2022.
  • For the 3-year period, Theravance Biopharma's Non Operating Income averaged around $1.9 million, with its median value being $1.5 million (2025).
  • As far as peak fluctuations go, Theravance Biopharma's Non Operating Income plummeted by 116.03% in 2021, and later soared by 1,761.45% in 2022.
  • Theravance Biopharma's Non Operating Income (Quarterly) stood at $338,000 in 2021, then soared by 1,001.18% to $3.7 million in 2022, then slumped by 50.38% to $1.8 million in 2023, then plummeted by 51.06% to $904,000 in 2024, then surged by 192.51% to $4.1 million in 2025.
  • Its Non Operating Income stands at $4.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $939,000 for Q1 2025.